AgomAb Therapeutics NV (AGMB) News
Follow AgomAb Therapeutics NV (AGMB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Agomab Therapeutics Experimental Drug Delivers Sustained Disease Control in Long-Term Crohn's Disease Trial
Agomab Therapeutics NV (NASDAQ: AGMB ) reported results from the 48-week open-label extension portion of its Phase 2a STENOVA trial of ontunisertib for fibrostenotic Crohn’s disease. • AgomAb Therapeutics stock is showin
LIVE | Oct 01, 2026, 06:31 PM UTC
L
Agomab Therapeutics Reports Positive Phase 1 Data for Lung Disease Drug
By Elias SchisgallAgomab Therapeutics said a phase 1 study for a lung disease treatment showed a reduction in a target protein, supporting the launch of a phase 2 study.The clinical-stage biopharmaceutical company said t
NEWS | Sep 14, 2026, 08:49 PM UTC
L
AGMB - Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
AGMB - Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study
NEWS | Sep 14, 2026, 08:05 PM UTC
L
Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
Antwerp, Belgium, September 11, 2026 — Agomab Therapeutics NV NASDAQ:AGMB ("Agomab" or the "Company"), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders
NEWS | Sep 11, 2026, 08:05 PM UTC
L
AGMB - Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
AGMB - Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors
NEWS | Sep 11, 2026, 08:05 PM UTC
L
Agomab management to participate in upcoming investor conferences
Agomab Therapeutics NV says members of its management team will participate in upcoming investor conferences.
EQUITY | Sep 03, 2026, 08:08 PM UTC
L
AGMB - Agomab to Participate in Upcoming Investor Conferences
AGMB - Agomab to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 08:05 PM UTC
L
BMO, Wedbush, Wolfe and RBC issue stock initiations
BMO, Wedbush, Wolfe, RBC and Cantor initiate coverage with ratings changes on AKTS, ALNY, ASND, BCAX, BMRN, CATX, PRME, AFL, AGMB, COR and MCK.
EQUITY | Aug 19, 2026, 11:09 AM UTC
M
AGMB Aligns With FDA
Agomab Therapeutics aligns with FDA on design of Phase 2b NOV-ERA study with Ontunisertib
EARNINGS | Jun 23, 2026, 08:10 PM UTC
M
AGMB Designs NOV-ERA Study
Agomab announces design of NOV-ERA Phase 2b study with Ontunisertib in Fibrostenosing Crohn's Disease
EQUITY | Jun 23, 2026, 08:05 PM UTC
M
Banks Initiate Coverage
Multiple banks initiate coverage on various stocks with different ratings
EQUITY | Jun 23, 2026, 10:55 AM UTC
M
CRDO: Credo Initiated
Credo Technology Group Holding Ltd initiated with Outperform rating and $325 price target by Evercore ISI Group analyst Mark Lipacis
EQUITY | Jun 22, 2026, 12:39 PM UTC
M
AGMB: HC Wainwright Initiates Buy
HC Wainwright & Co. initiates coverage on AgomAb Therapeutics with a buy rating and a price target of $35
EQUITY | Jun 22, 2026, 11:05 AM UTC